Artwork

Content provided by BMJ Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BMJ Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Alemtuzumab’s impact on functional and structural integrity of the visual system in MS

20:02
 
Share
 

Manage episode 307901704 series 9877
Content provided by BMJ Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BMJ Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Prof Michael Barnett, Director Sydney Neuroimaging Analysis Centre and Professor of Neurology, University of Sydney, joins JNNP's Podcast Editor, Colin Mahoney, to discuss how the use of Alemtuzumab may have longer-term impacts on improving one of the most commonly involved neurological pathways, the visual system, in multiple sclerosis (MS). Prof Barnett discusses his team's results after following up patients with highly active MS for 24 months, using multifocal visual evoked potentials and advanced neuroimaging. He also talks about what this means for future remyelination strategies.

Related paper: https://jnnp.bmj.com/content/92/12/1319

  continue reading

204 episodes

Artwork
iconShare
 
Manage episode 307901704 series 9877
Content provided by BMJ Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BMJ Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Prof Michael Barnett, Director Sydney Neuroimaging Analysis Centre and Professor of Neurology, University of Sydney, joins JNNP's Podcast Editor, Colin Mahoney, to discuss how the use of Alemtuzumab may have longer-term impacts on improving one of the most commonly involved neurological pathways, the visual system, in multiple sclerosis (MS). Prof Barnett discusses his team's results after following up patients with highly active MS for 24 months, using multifocal visual evoked potentials and advanced neuroimaging. He also talks about what this means for future remyelination strategies.

Related paper: https://jnnp.bmj.com/content/92/12/1319

  continue reading

204 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide